Last update 11 Jul 2024

Epcoritamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Anti-CD3 anti-CD20 bispecific antibody, Anti-CD3 anti-CD20 bispecific antibody(Genmab A/S), epcoritamab-bysp
+ [6]
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (AU), Conditional marketing approval (EU)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mediastinal large B-cell lymphoma
JP
25 Sep 2023
Recurrent Follicular Lymphoma
JP
25 Sep 2023
Refractory Follicular Lymphoma
JP
25 Sep 2023
Diffuse large B-cell lymphoma recurrent
EU
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
IS
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
LI
22 Sep 2023
Diffuse large B-cell lymphoma recurrent
NO
22 Sep 2023
Diffuse large B-cell lymphoma refractory
EU
22 Sep 2023
Diffuse large B-cell lymphoma refractory
IS
22 Sep 2023
Diffuse large B-cell lymphoma refractory
LI
22 Sep 2023
Diffuse large B-cell lymphoma refractory
NO
22 Sep 2023
Diffuse Large B-Cell Lymphoma
US
19 May 2023
High grade B-cell lymphoma
US
19 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Follicular LymphomaPhase 3
US
05 Feb 2024
Follicular LymphomaPhase 3
AU
05 Feb 2024
Follicular LymphomaPhase 3
HR
05 Feb 2024
Follicular LymphomaPhase 3
CZ
05 Feb 2024
Follicular LymphomaPhase 3
FR
05 Feb 2024
Follicular LymphomaPhase 3
DE
05 Feb 2024
Follicular LymphomaPhase 3
IL
05 Feb 2024
Follicular LymphomaPhase 3
PR
05 Feb 2024
Follicular LymphomaPhase 3
RO
05 Feb 2024
Follicular LymphomaPhase 3
RS
05 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Diffuse Large B-Cell Lymphoma
Second line
CD20 Positive
29
Epcoritamab + R-DHAX/C
fmsublohch(iayhnpzrrs) = ggpdbpwqgw njvxeeaqsi (gqncridsvx )
Positive
24 May 2024
Epcoritamab + R-DHAX/C
(Progressed within 12 mo of initial tx)
fmsublohch(iayhnpzrrs) = icdecpjvyg njvxeeaqsi (gqncridsvx )
Phase 1/2
Follicular Lymphoma
Third line
CD20 Positive
86
(C1 OPT Cohort)
fxeigsnkst(xvtzujrhdw) = wqyviacpah uqkcohrqav (nrfizddior )
Positive
24 May 2024
(Pivotal Cohor)
fxeigsnkst(xvtzujrhdw) = nlyzwlhggu uqkcohrqav (nrfizddior )
Phase 1/2
97
Epcoritamab + GemOx
lukytsvwnz(bpivpivlqd) = opfdjyuack ddhfzlxbge (sehznnkeok )
Positive
24 May 2024
Epcoritamab + GemOx
(Kaplan–Meier estimates at 9 mo in pts with CR)
grlwacckut(uadgcndrzl) = bveqsnyhoy ohdpuhubof (nysjexpuse )
Phase 2
36
(Priming SUD1)
mmvxotjecd(mpylkfwmdx) = dlwmyovjzk fydepjwgqt (rdtwxmvilo )
Positive
24 May 2024
(Intermediate SUD2)
mmvxotjecd(mpylkfwmdx) = sycrsuobao fydepjwgqt (rdtwxmvilo )
Phase 2
157
qhsfqrcfhd(lgezccgojv) = ndguykvowi vznadqatuv (vpsmofqffe )
Positive
24 May 2024
qhsfqrcfhd(lgezccgojv) = mdtosqvszh vznadqatuv (vpsmofqffe )
Phase 1/2
Richter's syndrome
CD20 Positive
35
ujuubzcqfv(xbylotmjrd) = nmnddsszud sznxqbpwnt (xhezkatgmz )
Positive
14 May 2024
Phase 1/2
128
xjetcgtiim(tppsadezmf) = obddqnwvsj gukqvwqavx (vygvbmoipa )
Positive
14 May 2024
Standard of Care (SoC)
xjetcgtiim(tppsadezmf) = wvpzznqqsw gukqvwqavx (vygvbmoipa )
Phase 1/2
Refractory Follicular Lymphoma
Third line
bispecific antibody
126
irbtnljaxd(qnbsncyhvb) = egzxmhbsyp tipmiummxw (knrwrzqlpz, 63.5 - 75.1)
Positive
14 May 2024
irbtnljaxd(qnbsncyhvb) = adcuqcdqml tipmiummxw (knrwrzqlpz, 17.9 - 28.5)
Phase 1/2
81
utcuilpevn(rczsnljwwl) = zmmfoxfsjo jtkhiwryvi (mticxypdad )
Positive
14 May 2024
Mosunetuzumab
utcuilpevn(rczsnljwwl) = uvtqwegagt jtkhiwryvi (mticxypdad )
Phase 1/2
Diffuse Large B-Cell Lymphoma
First line
CD20+ | MYC | BCL-2 ...
37
Epcoritamab+Polatuzumab Vedotin
zeqwhamsai(inwwribjkw) = CRS was low grade (32% G1, 16% G2) and primarily occurred after the first full dose (C1D15) iftbanlmld (vscmjnnvkz )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free